由于PCK1缺乏,MASH-HCC通过12-HETE诱导的CD8+ T细胞功能障碍进展
1Department of Infectious Diseases, Key Laboratory of Molecular Biology for Infectious Diseases (Ministry of Education), Institute for Viral Hepatitis, The Second Affiliated Hospital, Chongqing Medical University, Chongqing, China.
烯酸碳素激酶1 (PCK1) 对于与代谢功能障碍相关的肝炎相关的肝细胞癌 (MASH-HCC) 治疗至关重要. 恢复PCK1或抑制12-HETE可以提高抗PD-1治疗对MASH-HCC的有效性.
科学领域:
- 肝病学 肝病学是一种肝病学.
- 癌症生物学 癌症生物学
- 免疫学 免疫学 免疫学
背景情况:
- 与代谢功能障碍相关的肝炎相关的肝细胞癌 (MASH-HCC) 对免疫检查点抑制剂的反应有限.
- 这种降低的疗效可能源于瘤细胞代谢重编程和瘤微环境的改变.
研究的目的:
- 为了研究MASH-HCC.中葡萄糖生成酶酸酸碳素激酶1 (PCK1) 的作用.
- 探索PCK1与MASH-HCC.中瘤微环境之间的相互作用.
主要方法:
- 已建立的肝细胞特异性Pten和Pck1淘汰小鼠以模型MASH-HCC.
- 利用单细胞RNA测序和多参数流细胞测量来分析免疫场景的变化.
- 进行非向的代谢分析以确定肝脏代谢失调.
主要成果:
- 与相邻的非癌性组织相比,PCK1在MASH-HCC瘤组织中被下调.
- 肝细胞特异性Pck1淘汰赛小鼠显示瘤发生增加和CD8+ T细胞功效器功能受损.
- PCK1 缺乏导致12-基酸酸 (12-HETE) 积累,通过p38 MAPK通路引起CD8+ T细胞功能障碍.
- 恢复PCK1或抑制12-HETE,与抗PD-1相结合,增强了抗瘤免疫力,并抑制了MASH-HCC.
结论:
- 肝PCK1通过MASH-HCC中的12-HETE-p38信号传导在CD8+T细胞功能障碍中发挥关键作用.
- 在MASH-HCC中,PCK1代表了一个潜在的代谢标,可以提高抗PD-1免疫疗法的疗效.
更多相关视频
09:13Author Spotlight: Identifying Compensatory Pathways in Malaria Parasites Containing Hypomorphic Allele of Essential Protein Kinases
Published on: November 22, 2024
08:34Utilizing Murine Inducible Telomerase Alleles in the Studies of Tissue Degeneration/Regeneration and Cancer
Published on: April 13, 2015
相关概念视频
M-Cdk Drives Transition Into Mitosis
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Abnormal Proliferation
Inhibition of Cdk Activity
Anaphase Promoting Complex
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
